ID: ALA22978

Max Phase: Preclinical

Molecular Formula: C20H20FN3O2

Molecular Weight: 353.40

Molecule Type: Small molecule

Representations

Canonical SMILES:  CN1CCC(O)(c2nc(-c3ccc(F)cc3)c(-c3ccncc3)o2)CC1

Standard InChI:  InChI=1S/C20H20FN3O2/c1-24-12-8-20(25,9-13-24)19-23-17(14-2-4-16(21)5-3-14)18(26-19)15-6-10-22-11-7-15/h2-7,10-11,25H,8-9,12-13H2,1H3

Standard InChI Key:  OLWWIAFRNOFHTL-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 353.40

Molecular Weight (Monoisotopic): 353.1540

AlogP: 3.46

#Rotatable Bonds: 3

Polar Surface Area: 62.39

Molecular Species: NEUTRAL

HBA: 5

HBD: 1

#RO5 Violations: 0

HBA (Lipinski): 5

HBD (Lipinski): 1

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 12.52

CX Basic pKa: 8.10

CX LogP: 2.00

CX LogD: 1.22

Aromatic Rings: 3

Heavy Atoms: 26

QED Weighted: 0.78

Np Likeness Score: -0.64

References

1. Revesz L, Di Padova FE, Buhl T, Feifel R, Gram H, Hiestand P, Manning U, Zimmerlin AG..  (2000)  SAR of 4-hydroxypiperidine and hydroxyalkyl substituted heterocycles as novel p38 map kinase inhibitors.,  10  (11): [PMID:10866395] [10.1016/s0960-894x(00)00200-6]

2. Revesz L, Blum E, Di Padova FE, Buhl T, Feifel R, Gram H, Hiestand P, Manning U, Rucklin G..  (2004)  Novel p38 inhibitors with potent oral efficacy in several models of rheumatoid arthritis.,  14  (13): [PMID:15177482] [10.1016/j.bmcl.2004.03.106]

Source

Source(1):

• Scientific Literature